Drug Trial Radar · NCT07722962
Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jul 31, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Kringle Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.
Conditions
- Acute Spinal Cord Injury (SCI)
Interventions
KP-100ITDrug
The contents of each vial were dissolved in the distilled water for injection, and the study drug (0.6 mg as KP-100) was administered intrathecally once per week a total of 5 times.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with an improvement of at least two AIS (American Spinal Injury Association) grade, A to C/D, at 24 weeks after administration, 24 weeksTime frame: 24 weeks after investigational product administration
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Japan Organization for Occupational Health and Safety Comprehensive Spinal Cord Injuries Center
Iizuka, Fukuoka, Japan
Japan Organization for Occupational Health and Safety Hokkaido Spinal Cord Injury Center
Bibai, Hokkaido, Japan
National Hospital Organization Murayama Medical Center
Musashimurayama, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.